Frankfurt
24.01.25
15:29 Uhr
1,882 Euro
-0,092
-4,66 %
-4,66 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| Do | Advicenne Announces 2024 Gross Sales1 | 177 | Business Wire | 2024 Gross sales reported at €4.8 million, up 9.2%. Gross sales of Sibnayal® (potassium citrate potassium bicarbonate) in France recorded an impressive 40% growth. Royalties for 2024... ► Artikel lesen | |
| 19.12.24 | Advicenne Finalizes Agreement with Primex Pharmaceuticals AG | 319 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 28.11.24 | Advicenne Announces its 2025 Financial Calendar | 75 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 01.10.24 | Advicenne achieves major milestones in the US thanks to several positive FDA opinions on ADV7103 | 342 | Business Wire | FDA agrees to submission of a marketing authorization application for ADV7103 in dRTA without further clinical studies. The positive orphan drug designation decision for ADV7103 in cystinuria... ► Artikel lesen | |
| 18.09.24 | Advicenne Reports Its First Half Financial Results as of June 30, 2024, and Updates on Its Activities | 340 | Business Wire | Sibnayal® gross sales up 28% to €1.25 million including royalties paid by commercial partners (16% excluding royalties) Continued progress towards current operating breakeven Cash... ► Artikel lesen | |
| 18.07.24 | Advicenne Announces an 8.8% Increase in Gross Sales for H1 2024 and Provides an Update on Its Activities | 325 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 15.05.24 | Advicenne Announces the Approval of All Resolutions Supported by the Board of Directors at Its Combined General Meeting | 259 | Business Wire | Regulatory News:
The Combined General Meeting of shareholders of Advicenne (Euronext Growth Paris ALDVI FR0013296746) (Paris:ALDVI), a specialty pharmaceutical company dedicated to the development... ► Artikel lesen | |
| 28.03.24 | Advicenne: Strong improvement of 2023 results thanks to sustained commercial activity on Sibnayal | 485 | Business Wire | Sibnayal volume up 84%.
Gross sales exceed €4 million for the first time.
Sharp decrease in net loss to -7.03 M€ vs. -11.47 M€ in 2022.
Year-end cash position at €5.25 million... ► Artikel lesen | |
| 25.03.24 | Advicenne: FDA Grants Orphan Drug Designation to ADV7103 for the Treatment of Cystinuria. | 499 | Business Wire | After distal Renal Tubular Acidosis (dRTA) in December 2022, ADV7103 is granted "orphan drug" status in the United States in cystinuria. A long-awaited milestone for the Company and its flagship... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 24,870 | -1,97 % | Pfizer Aktie: Was Analysten zu berichten haben | Die US-amerikanische Pharmafirma Pfizer steht aktuell vor wichtigen strategischen Veränderungen. Der Konzern plant bedeutende Verkaufsaktivitäten, während die Aktie am letzten Handelstag bei 26,31 USD... ► Artikel lesen | |
| ABBVIE | 162,66 | -0,71 % | AbbVie To Collaborate With Neomorph To Develop Molecular Glue Degraders For Oncology And Immunology | WASHINGTON (dpa-AFX) - AbbVie, Inc. (ABBV) and Neomorph, Inc. announced Thursday a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets... ► Artikel lesen | |
| HALEON | 4,472 | -0,78 % | Pfizer Sells GBP 2.50 Bln Of Shares In Haleon | NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) Wednesday announced the sale of 700 million shares in Haleon Plc (HLN), a British multinational consumer healthcare company, at 357 pence per share... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 111,00 | 0,00 % | ROUNDUP: Ligand Pharmaceuticals Boosts FY24 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the third quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) raised its core adjusted earnings and... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 2,900 | +1,22 % | Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory | ||
| ROYALTY PHARMA | 28,900 | -1,67 % | Why Is Andreas Halvorsen Bullish On Royalty Pharma plc (RPRX) Now? | ||
| TG THERAPEUTICS | 27,320 | -0,51 % | Here's Why Analysts Are Bullish on TG Therapeutics, Inc. (TGTX) | ||
| EISAI | 27,710 | -1,46 % | Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company | TOKYO, Jan 22, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been listed in the 2025 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based... ► Artikel lesen | |
| VERONA PHARMA PLC ADR | 52,50 | +0,96 % | AKTIONÄR-Tipp Verona Pharma nicht zu stoppen - Leser 155 Prozent im Plus | Beim Blick auf den Chart von Verona Pharma stockt einem der Atem. Trotz Top-Performance im vergangenen Jahr eilt der Wert auch im Jahr 2025 von einem Allzeithoch zum nächsten. Anleger und Analysten... ► Artikel lesen | |
| DR REDDYS | 13,300 | -1,48 % | Dr. Reddy's Q3 & 9MFY25 Financial Results | HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and... ► Artikel lesen | |
| INTRA-CELLULAR THERAPIES | 122,00 | 0,00 % | Johnson & Johnson Projects 2025 Adj. Operational EPS Growth Of 8.7% At Midpoint, Excl. ITCI | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) said the company expects fiscal 2025 adjusted EPS in a range of $10.50 - $10.70, which represents a growth of 6.2%, at midpoint. Adjusted operational... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,093 | -8,42 % | BETTERLIFE HLDG (06909): SUPPLEMENTAL ANNOUNCEMENT TO THE VERY SUBSTANTIAL ACQUISITION AND PROVISION OF FINANCIAL ASSISTANCE | ||
| ENTOURAGE HEALTH | 0,001 | 0,00 % | Entourage Health Corp. Enters into Arrangement Agreement for Going-Private Transaction | TORONTO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE: 4WE) (the "Company" or "Entourage") is pleased to announce that it has entered into a definitive... ► Artikel lesen | |
| KYOWA KIRIN | 14,200 | +0,71 % | Dividendenbekanntmachungen (27.12.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADWAYS INC JP3121970002 3 JPY 0,0182 EUR AGC INC JP3112000009 105 JPY 0,6373 EUR ALERUS FINANCIAL CORPORATION US01446U1034 0... ► Artikel lesen | |
| IGC PHARMA | 0,340 | +1,19 % | IGC Pharma, Inc.: IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor | POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.
